ADMA vs. NMRA, TARS, FDMT, INBX, FUSN, VIR, BEAM, CGEM, SRRK, and DNA
Should you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include Neumora Therapeutics (NMRA), Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), Inhibrx (INBX), Fusion Pharmaceuticals (FUSN), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Cullinan Oncology (CGEM), Scholar Rock (SRRK), and Ginkgo Bioworks (DNA). These companies are all part of the "biological products, except diagnostic" industry.
Neumora Therapeutics (NASDAQ:NMRA) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
ADMA Biologics received 395 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Neumora Therapeutics an outperform vote while only 71.68% of users gave ADMA Biologics an outperform vote.
Neumora Therapeutics has a net margin of 0.00% compared to Neumora Therapeutics' net margin of -1.29%. Neumora Therapeutics' return on equity of 17.24% beat ADMA Biologics' return on equity.
ADMA Biologics has higher revenue and earnings than Neumora Therapeutics.
Neumora Therapeutics presently has a consensus price target of $22.57, suggesting a potential upside of 133.42%. ADMA Biologics has a consensus price target of $10.50, suggesting a potential upside of 14.01%. Given ADMA Biologics' higher possible upside, equities analysts plainly believe Neumora Therapeutics is more favorable than ADMA Biologics.
47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, ADMA Biologics had 6 more articles in the media than Neumora Therapeutics. MarketBeat recorded 11 mentions for ADMA Biologics and 5 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.66 beat ADMA Biologics' score of 0.17 indicating that ADMA Biologics is being referred to more favorably in the news media.
Summary
ADMA Biologics beats Neumora Therapeutics on 11 of the 15 factors compared between the two stocks.
Get ADMA Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADMA Biologics Competitors List
Related Companies and Tools
